Reactogenicity and antigenic activity of recombipants obtained by crossing cold-adapted donor of attenuation A/Leningrad/134/47/57 with wild-type influenza virus strains A/Leningrad/322/79(HlN1) and A/ Bangkok/1/79(H3N2) were studied. The recombinants were areactogenic when administered as an intranasal spray to children aged 3 to 15, including those who lacked or had only low titers of pre-existing antihemagglutinin and anti-neuraminidase antibody in their blood. After two administrations of vaccines at a 3-week interval, both strains induced antibody in 75 to 95% of the children. On coinfection of chicken embryos with both recombinants, only weak interference was observed. Administration to children of the bivalent vaccine containing HlNl and H3N2 recombinants induced efficient production of antibody to Hi and H3 hemagglutinins and Ni and N2 neuraminidases without adverse reactions. The recombinants studied were genetically stable as judged by retention of the temperature-sensitive phenotypes and a lack of reversion of the genes carrying temperature-sensitive mutations in all of the reisolates from vaccinated children.
Bangkok/1/79(H3N2) were studied. The recombinants were areactogenic when administered as an intranasal spray to children aged 3 to 15, including those who lacked or had only low titers of pre-existing antihemagglutinin and anti-neuraminidase antibody in their blood. After two administrations of vaccines at a 3-week interval, both strains induced antibody in 75 to 95% of the children. On coinfection of chicken embryos with both recombinants, only weak interference was observed. Administration to children of the bivalent vaccine containing HlNl and H3N2 recombinants induced efficient production of antibody to Hi and H3 hemagglutinins and Ni and N2 neuraminidases without adverse reactions. The recombinants studied were genetically stable as judged by retention of the temperature-sensitive phenotypes and a lack of reversion of the genes carrying temperature-sensitive mutations in all of the reisolates from vaccinated children.
In an accompanying paper (5), we presented data on obtaining a cold-adapted donor of attenuation and its coldadapted recombinants and on molecular genetic analysis of these strains. This paper presents data on evaluation of reactogenicity and antigenicity of recombinant vaccines for children aged 3 to 15 and analysis of isolates from the vaccinees.
MATERIALS AND METHODS
The viruses and preparation of the recombinants have been described previously (5) .
Vaccine and placebo. Experimental vaccines were prepared with the cold-adapted recombinants in accordance with requirements currently existing in the USSR. Monovalent vaccines contained 107-5 50% egg infective doses (EID50) of infectious recombinant virus per ml. The vaccines were diluted 1:2 before administration. Bivalent vaccine was prepared by mixing two undiluted monovalent vaccines just before administration. Placebo consisted of normal allantoic fluid of uninfected chicken embryos diluted 1:2 before administration.
Vaccination of humans. Vaccine was administered in 0.25-ml volumes (107 0 EID50 of the virus) intranasally into each nasal turbinate with a sprayer. Revaccination was carried out 21 days later by the same method. Evaluation of reactogenicity of vaccines. Evaluation of reactogenicity of the cold-adapted recombinant vaccines was carried out in stages. First, healthy young adults aged 18 to 25 years were vaccinated. Then, schoolchildren aged 12 to 15 and 7 to 11 years and children 3 to 6 years of age were vaccinated. Children were immunized in organized communities (schools and preschools) in February-March 1981. It should be noted that no influenza morbidity was registered during that period in the city where the vaccinations were * Corresponding author.
carried out, and no influenza viruses were isolated. Children and adults were carefully examined before vaccination to select healthy individuals, who were then divided into two equal groups. Children of the first group received vaccine, whereas those in the other received an indistinguishable placebo. They were observed for 5 days after the first vaccination for evaluation of their systemic and local reactions and temperature measurement.
Evaluation of antigenic activity. Paired sera were taken from vaccinated children before vaccination, 21 days after the first vaccination, and 21 days after the second vaccination to determine anti-hemagglutinin (anti-HA) titers in a hemagglutination test modified by Alexandrova (1) . To remove nonspecific inhibitors, sera were heated at 58°C for 30 min; to determine antibody levels to H3 hemagglutinin, a variant of AlBangkok/1/79(H3N2) influenza virus resistant to nonspecific inhibitors of blood serum was used as a test virus. Anti-neuraminidase (anti-NA) antibody levels were determined in an elution-inhibition test (2, 10) . The latter test was performed with recombinants R-11 (Heql-NA/BrazilIll/ 78) and R-17 (Heql-NA/Bangkok/1/79) as antigens. These recombinants were provided by N. E. Gorev (All-Union Influenza Institute, Leningrad, USSR). It should be noted that the variant of the method used by us for determining anti-NA antibody correlated well with a conventional one (10) .
Recombination test. The recombination test with reisolates fromn vaccinated children has been described previously (4, 6) and in the accompanying paper (5) . RESULTS Reactogenicity of monovalent vaccines prepared from recombinants 47/25/1(HlN1) and 47/7/2(H3N2). Only 1 of 122 (0.8%) young adults (including 65 persons with anti-HA titers of <16) vaccinated once with the 47/25/1(HlN1) strain developed fever (-37.6°C), which was transient ( Table 1) . Administration of the 47/7/2(H3N2) vaccine to 138 young Studies of genetic stability of the recombinants and isolates. To study the genetic stability of the recombinants, we passaged them five times in chicken embryos at 32°C, after which we compared the temperature-sensitive (ts) phenotype of the passaged and initial viruses. The passaged variants failed to reproduce at 40°C and retained the ts phenotype of the initial recombinants (not shown).
Next we studied the properties of isolates obtained from nasal swabs of children 48 h after vaccination with the coldadapted recombinant strains and passaged once in chicken embryos at 32°C. All isolates obtained from 23 children 3 to 15 years of age entirely retained the ts phenotype of the vaccines administered to children (Table 5) .
On the assumption that the recombinants used may have had ts mutations in several genes so that alterations in one of them during reproduction in the nasopharynx of the vaccinated children might have no effect on a ts phenotype of the reisolated virus, we decided to study the genetic properties of the isolates in a recombination analysis with the reference fowl plague virus ts mutants. All 14 isolates obtained from children 48 h after vaccination with recombinant 47/25/1 and all 9 isolates obtained from children 48 h after vaccination with recombinant 47/7/2 and passaged once in chicken embryos at 32°C behaved in these recombination experiments similarly to the vaccine recombinants administered to the children, i.e., they retained ts mutations in all the genes in which they were present in the initial recombinant strains used as monovalent vaccines (Table 5) . DISCUSSION Evaluation of reactogenicity of the cold-adapted recombinants showed that they caused transient fever in less than 1% of the vaccinees. No alterations in the general condition of the vaccinated children or any symptoms characteristic of acute respiratory diseases were observed. Cold-adapted recombinant vaccines obtained by using a cold-adapted A/Ann Arbor/6/60 strain as a donor of attenuation and which inherited five or six genes coding for nonglycosylated proteins from the cold-adapted donor also proved to be poorly reactogenic for adults with low initial antibody levels (3, 7-9), although they caused systemic afebrile reactions and catarrh symptoms in some volunteers (9) . As judged by measurement of hemagglutinin and neuraminidase antibody response, the cold-adapted recombinant strains obtained by us had an adequate immunogenicity, even for children with low initial antibody titers. A two-dose immunization induced a fourfold or greater antibody rise in 75.0 to 95.0% of the vaccinees; even after a one-dose immunization, a fourfold antibody rise was observed in over 60% of the vaccinated children. In addition, a fourfold or higher rise in anti-NA antibody was observed in 50 to 70% of the vaccinees.
A good antigenic response was achieved in recent investigations by Wright et al. (11) involving vaccination of 21 seronegative children with cold-adapted recombinant strains derived from the cold-adapted donor A/Ann Arbor/6/60. A fourfold increase in titers of anti-HA antibody was observed in the majority of children even after the single dose of vaccine.
It should be emphasized that wild-type H3N2 and HlNl influenza virus strains used by us to obtain recombinants had had only a few passages in chicken embryos at 32°C after isolation. In addition, special variants which grew well at 40°C were selected and used in recombination experiments.
Wide experience gained in the USSR in obtaining attenuated influenza virus strains used as live vaccines by passages in chicken embryos at the optimal temperature has shown that not less than 20 passages are required to obtain variants attenuated for humans. Lately, trials in volunteers of potentially reactogenic influenza virus strains have been prohibited in the USSR. Because of this we had no chance to evaluate reactogenicity for humans of the epidemic strains A/Leningrad/322/79(HlN1) and A/Bangkok/1/79(H3N2), which had had not more than six to eight passages in chicken embryos at optimal temperatures and might have retained the reactogenicity. Nevertheless we cannot rule out the possibility that the high degree of attenuation of the recombinants obtained may be due not only to the genes inherited from cold-adapted donor but also to ones derived from wildtype influenza virus. But it should be noted that in previous work (4) the transfer of genes coding for hemagglutinin and neuraminidase from the epidemic influenza virus strains whose reactogenicity was confirmed in volunteer trials did not change the degree of attenuation of recombinants which had inherited other genes from the cold-adapted parent.
The recombinants obtained by us were not overattenuated and their antigenic activity is associated with the ability to reproduce in the vaccinee organism. This is indicated by the ability to isolate viruses possessing properties of vaccine strains from nasal swabs of vaccinated children. In addition, it is very unlikely that intranasal administration of a very small virus dose (ca. 30 CCA) might have induced such a marked antigenic response without virus reproduction, which we observed in our experiments. According to data in the literature, inactivated influenza vaccine intranasally administered to children, even at a dose of 400 to 800 CCA, induced a very moderate antigenic response (12) .
We have also shown that it is possible to simultaneously use two recombinant strains in a bivalent vaccine of HlNl and H3N2 serotype, and in this instance the antigenic response of vaccinated children proved to be similar to that after separate administration of each preparation. Analysis of isolates from the vaccinees has shown that the virus contained in swabs retained a ts phenotype; at the same time, efficiency of plaquing at 39°C increased after one passage of the isolates in MDCK cells at 32°C, indicating a certain genetic instability of the vaccines under study. It should be emphasized that in our experiments we examined isolates which had had one passage in chicken embryos at 32°C after isolation; however, all of them proved to be entirely stable.
Attenuation of cold-adapted donors which had had multiple passages in chicken embryos might be due to ts, coldadapted, host-range, or other types of mutations. Possibly, multiple passages at a lowered temperature, as used to prepare the cold-adapted donor strain, might result in appearance of not only a single but several mutations in the same gene, and reversion (or suppression) of a single mutation would have no effect on the phenotype of the gene as a whole.
The data presented in this report and in an accompanying paper (5) indicate that the cold-adapted ts A/Leningrad/134/ 47/57(H2N2) strain was a satisfactory donor of attenuation to obtain recombinant live vaccine strains for immunization of children.
It should be noted in conclusion that in autumn of 1983 we vaccinated nearly 20,000 children 3 to 15 years of age with the cold-adapted recombinants 47/7/2(H3N2) and 47/25/1 (HlNl) and observed no adverse reactions, although the epidemiological activity was high (manuscript in preparation).
